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Abstract
Background: Several choices of inotropic therapy are available and used in relation to cardiac surgery. Comparisons are
necessary to select optimal therapy. In Denmark, dobutamine and milrinone are the two inotropic agents most commonly
used to treat post-bypass low cardiac output syndrome. This study compares all-cause mortality with these drugs.
Methods: In a retrospective observational study we investigated 10,700 consecutive patients undergoing cardiac surgery
from 1 April 2006 to 31 December 2013 at Aarhus and Aalborg University Hospitals in the Central and Northern Denmark
Region. Prospectively entered data in the Western Danish Heart Registry on intraoperative use of inotropes were
used to identify 952 patients treated with milrinone, 418 patients treated with dobutamine, and 82 patients
receiving a combination of the two inotropes. All-cause mortality among patients receiving dobutamine was
compared to all-cause mortality among milrinone receivers.
Multiple logistic regression analyses including preoperative and intraoperative variables along with g-formula
analyses were used to model 30-day and 1-year mortality risks. Reported were standardized mortality risk differences
between the treatment groups.
Results: Among patients receiving intraoperative dobutamine, 18 (4.3%) died within 30 days and 49 (11.7%) within 1
year. Corresponding 30-day and 1-year mortality for milrinone receivers were 81 (8.5%) and 170 (17.9%). Risk of death
within 30 days and 1 year was increased for intraoperative milrinone compared to dobutamine with a standardized risk
difference of 4.06% (confidence interval (CI) 1.23; 6.89, p = 0.005) and 4.77% (CI 0.39; 9.15, p = 0.033), respectively. Sensitivity
analyses including adjustment for milrinone preference, hemodynamic instability prior to cardiopulmonary bypass, and
separate analyses on hospital level all confirmed a sign toward increased mortality among milrinone receivers.
Conclusions: Intraoperative use of milrinone in cardiac surgery may be associated with an increase in all-cause mortality
compared to use of dobutamine.
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Background
Low cardiac output syndrome is a common complication
in cardiac surgery patients, occurring in 3–14% of patients
who undergo cardiac surgery with use of cardiopulmonary
bypass [1, 2]. Definitions of low cardiac output syndrome
vary, but most often include decrease in cardiac index to
< 2.0 L/min/m2, low systolic blood pressure < 90 mmHg,
and signs of tissue hypoperfusion [3]. Inotropic agents
form the cornerstone in the perioperative management of
low cardiac output syndrome along with mechanical assist
device support. Inotropic therapy is known to improve
intraoperative hemodynamic variables [4]. However, con-
cern has been raised regarding possible harmful side effects
of inotrope treatment such as arrhythmias, increased myo-
cardial oxygen consumption resulting in cardiac ischemia,
and potential damage of hibernating but viable myocardium
[5, 6]. Thus, despite the apparent immediate clinical
improvement achieved with inotrope therapy, there may be
a risk of progression of heart failure in patients exposed to
inotropes. Noticeably, there is substantial variation in choice
of inotropic therapy between cardiac centers and even
between individual providers within centers [7, 8], indicating
a lack of convincing data on how the most used inotropes
compare. Except for recent levosimendan trials [2, 9], in the
setting of cardiac surgery not a single randomized clinical
trial has ever investigated inotropes/vasopressors using hard
outcome parameters including mortality. Hence, data on
comparative efficacy or harm associated with individual
inotropic drugs are needed. In Denmark, dobutamine and
milrinone are the two inotropic agents most commonly
used to treat post-bypass low cardiac output syndrome.
Differences between milrinone and dobutamine therapy on
hemodynamic effects during cardiac surgery have been
investigated in only two randomized trials [10, 11]. These
trials included 120 and 20 patients, respectively and were
not designed to clarify the effects of drugs on mortality and
major postoperative complications. Consequently, data on
patient outcome following dobutamine versus milrinone
treatments have not been subjected to systematic trials and
both drugs are commonly used in the same centers.
Although meta-analytic data have shown a signal toward
increased mortality in cardiac surgery patients randomized
to receive milrinone [12], milrinone has become more and
more popular among Danish cardiac anesthesiologists.
Given the lack of trial data, we performed a large-scale
retrospective study of patients treated with intraoperative
dobutamine or milrinone during cardiac surgery to compare
all-cause mortality at 30 days and after 1 year.
Methods
Study design and setting
The study was set up as a two-center retrospective cohort
study based on prospectively registered data involving
10,700 consecutive adult patients undergoing cardiac
surgery in the Central and Northern Denmark Region at
the Aarhus and Aalborg University Hospitals, Denmark.
These hospitals provide cardiac surgery for a mixed rural–
urban population constituting 33% of the Danish popu-
lation. The Danish National Health Service provides
tax-funded medical care for all Danish residents. This
study followed a prespecified analysis plan, including
prespecified outcomes, exposures, confounders, and effect
modifications and prespecified identification of subgroups
for sensitivity analyses. The reporting follows the checklist
proposed in the STROBE statement [13].
Inclusion criteria
Patients older than the age of 14 years undergoing cardiac
surgery in the period from 1 April 2006 to 31 December
2013 were included provided they met the following inclu-
sion criteria: coronary artery bypass grafting (CABG), CABG
with valve surgery, valve surgery alone or combined with
other procedures, or surgery involving the thoracic aorta.
Patients with no valid civil registration number, no available
data on procedure type, or no information on exposure to
inotropes were excluded. Patients were excluded if they had
undergone heart transplants, pulmonary thromboendarter-
ectomy, only explorative sternatomy, or surgery for grown-
up congenital heart disease. Patients undergoing more than
one cardiac surgical procedure during the study period were
included with only the last surgical procedure.
Finally, patients receiving no inotrope therapy or inotrope
therapy other than dobutamine or milrinone were excluded,
leaving 1452 patients for study analyses (Fig. 1).
Data sources
Data were obtained from the Western Denmark Heart
Registry. Registration is mandatory and Internet based,
and is completed intraoperatively and postoperatively in
the intensive care unit by the surgeons and the attending
anesthetists. The registry includes detailed information
on patient history, type of procedure, and intraoperative
and postoperative management including inotropic therapy
and inhospital complications. Data quality is assessed using
automatic validation rules at data entry combined with
systematic validation procedures and random spot-checks
of data after entry. Coverage of the Western Denmark
Heart Registry is routinely evaluated by comparison with
data from the Danish National Patient Register including
data on all procedures performed in both private and
public hospitals in Denmark. These analyses have shown a
high coverage of the Western Denmark Heart Registry, with
more than 95% reporting all CABG procedures. Random
samples of the data in the Western Denmark Heart Registry
have been validated against local patient files (both elec-
tronic and paper files). The quality control of the WDHR
has revealed that overall data errors were lower than 3%
[14]. The Western Denmark Heart Registry has proven a
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valuable data source in research, providing ongoing
longitudinal registration of detailed data on patients
and procedures [15]. Missing data in the registry were
retrieved from local patient files (both electronic and
paper) and overall missing data in the study cohort
constituted less than 0.3% for covariates retrieved from
registry and 0% for outcome data.
Registration of intraoperative hemodynamic variables
was restricted to Aarhus University Hospital, where data
were obtainable from a perioperative electronic database
management system. Due to random electronic errors,
some hemodynamic variables were lost for registration
in approximately one-third of these cases.
Intraoperative management
All preoperative cardiac medication was continued until
the morning of surgery except for angiotensin-converting
inhibitors, aspirin, and platelet function inhibitors. Beta-
blocking agents were continued on the day of surgery in
chronically treated patients. All patients received standard
premedication in the form of a benzodiazepine 60–90 min
before surgery. Our perioperative management strategies
have been described in detail previously [16]. Briefly,
all patients received general anesthesia with invasive
hemodynamic monitoring, including use of a pulmonary
artery catheter (standard Swan-Ganz catheter; Edwards
Lifesciences, Irvine, CA, USA) with or without continuous
cardiac output measurements and transesophageal echo-
cardiography. The standardized cardiopulmonary bypass
(CPB) technique included use of a closed system with a
modified additive coating system and a venous reservoir,
priming with crystalloid, and routine blood flow rates at
2.4 L/min/m2 aiming at a mean arterial pressure of 50–60
mmHg. Patients were maintained norm thermic or mildly
hypothermic. Myocardial protection was achieved by
either intermittent antegrade cold crystalloid or blood
Fig. 1 Flowchart of study cohort
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cardioplegia with 20-min intervals. Cardioplegia was
given retrograde when appropriate. At the end of the
surgical procedure, reperfusion of the heart was performed
on an individual basis according to the patient’s general
condition and time on cross clamp. Use of calcium at the
termination of CPB was at the discretion of the attending
anesthesiologist. At the end of surgery, patients were
transferred to the intensive care unit (ICU). There was
no fixed postoperative treatment regimen for either
pharmaceutical or mechanical support. Patients were
extubated when they were hemodynamic stable and
with no need of respiratory support. Following routine
practice, patients were discharged from the ICU to the
general ward within the first postoperative day, on condi-
tion of being clinically stable and with no need for
hemodynamic or respiratory support.
Inotropic treatment
Neither institutional guidelines nor specified algorithms
dictating intraoperative inotropic therapy were used in
the participating centers. Consequently, the intraoperative
strategy of inotrope use and discontinuation of inotrope
use were at the discretion of the attending anesthetist.
However, if inotrope treatment was considered necessary,
the standard procedure in both centers was to initiate ino-
trope treatment at the end of, or after CPB. Patients who
had received dobutamine in any dosage intraoperatively
either as single therapy or with concurrent vasoconstrictor
infusion were classified as exposed to “intraoperative
dobutamine”. Patients who had received milrinone admin-
istered as infusion or/and as bolus while on CPB with or
without concurrent vasoconstrictor infusion were classi-
fied as exposed to “intraoperative milrinone”. Patients
who had received both inotropes during operation were
classified as “intraoperative combination”. Data on intra-
operative inotrope therapy was entered prospectively in
the Western Danish Hearth Registry.
Primary outcome measure
The primary outcomes of this study were 30-day and 1-year
all-cause mortality. Date of death was obtained from the
Civil Registration System [17]. All patients in the study
cohort had at least 1 year of follow-up after discharge
from the ICU. None of the 1452 patients included in the
analyses presented missing data on mortality outcomes.
Confounders
In an earlier study, we identified patient and procedural
factors associated with use of inotropic therapy in cardiac
surgery [7]. These potential confounding factors were
collected through the Western Danish Heart Registry
and included the additive EuroSCORE I [18, 19], type
of cardiac procedure, time on CPB, attending anesthetist
preference of inotrope drug, cardiac center, anesthetic
technique, and year of surgery. Left ventricular function
and type of surgery might strongly influence decision-
making with respect to inotrope use, and weighting in the
EuroSCORE score might not reflect this; consequently,
these variables were analyzed separately. To avoid including
confounding factors twice (both as single parameters and in
the EuroSCORE), a modified version of the EuroSCORE
was designed, excluding gender, age, left ventricular func-
tion, and type of cardiac surgery. The modified EuroSCORE
with included variables and scoring is presented in
Additional file 1: Table S1. Cardiac procedures were
separated into three groups: CABG-only group, aortic
valve repair or replacement only or in combination with
other procedure group, and mitral valve repair or re-
placement only or in combination with other procedure
group. Time on cardiopulmonary bypass was grouped
as offpump, less than or equal to 120 min, or exceeding
120 min. Anesthetic techniques were expressed as
intravenous anesthesia or volatile anesthesia. When
available, the precardiopulmonary cardiac index (L/min/
m2) and mixed venous oxygen saturation were included as
confounders. A mean of four consecutive measurements
every 15 min within 1 h prior to cardiopulmonary bypass
was included for analyses.
Statistical methods
Preoperation patient characteristics were summarized
according to the treatment groups (intraoperative milrinone,
intraoperative dobutamine, and intraoperative combination
therapy), and compared across treatment groups using
chi-square tests for categorical variables and analysis of
variance for continuous variables. Crude 30-day and 1-year
mortality were computed and reported as relative frequen-
cies. Patient characteristics and procedural factors may
confound a direct comparison of relative mortality frequen-
cies between patients receiving milrinone compared to
dobutamine receivers. Therefore, the main analysis was
based on a multiple logistic regression model for 30-day
and 1-year mortality outcome according to milrinone
versus dobutamine treatment or combination therapy and
further adjusted for age (< 60 years, 60–69 years, 70–75
years, > 75 years), gender, left ventricular ejection fraction
(≤ 30%, 31–50%, > 51%), cardiac procedure type, time on
cardiopulmonary bypass (off-pump, ≤ 120 min, > 120 min),
type of anesthesia, year of surgery, and modified total
EuroSCORE.
To enable a clinical interpretation, causal inference
methodology was implemented [20].
Theoretically, a detrimental effect of one of the drugs
could be masked by patients having a beneficial effect of
the other drug received postoperatively. Such an effect
would result in the intraoperative combination having a
lower mortality than at least one of the drugs used alone.
Accordingly, combination therapy with both dobutamine
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and milrinone was included in the data analysis. Because
there were three groups of treatment, propensity matching
was not used and the g-formula model was used instead.
The g-formula model uses the derived logistic model to
predict outcome for the whole population for each of the
three treatment groups, thereby ensuring identical covariate
status for the comparison. The derived differences in
mortality are thereby adjusted for all confounders, but still
depend on the model being appropriate and the absence
of unmeasured confounding.
From the logistic regression analysis, we computed
three standardized mortality risks for each patient using the
g-formula approach [21–23]. With “standardized mortality
risks”, we refer to the probability that a patient with a given
combination of risk factors dies within 30 days or within 1
year according to our logistic regression model. For the first
(second, third) standardized mortality risks, we predicted
the probability of 30-day or 1-year mortality conditioning
on actual values of the confounders but assuming possible
counter to the fact that all patients received dobutamine
(milrinone, combination therapy). Reported were differ-
ences in averages of standardized 30-day and 1-year
mortality risks between dobutamine versus milrinone
treatment or combination therapy. Confidence intervals
and Wald tests for the standardized risk differences
were obtained using bootstrap standard errors based on
5000 bootstrap samples.
We included milrinone preference as an additional
confounder to determine whether there was an influence
if the attending anesthetist had a preference for using
milrinone as inotropic therapy. Only anesthetists who
had been attending surgeries during the entire study
period were included for this analysis, leaving 872 patients
for analysis. Preference status was based on frequency of
milrinone use in the first half of study period, grouping
each anesthetist into quartiles: use of milrinone for less
than 48% of his/her patients, 48–70% of his/her pa-
tients, 71–83% of his/her patients, or more than 84% of
his/her patients in this baseline period. Accordingly,
the numbers in each treatment group refer to the num-
bers of patients anesthetized by doctors assigned to
each of the four quartiles of milrinone preference.
Further, to determine whether the hemodynamic status
immediately before initiating cardiopulmonary bypass modi-
fied the results, a sensitivity analysis was performed in the
subset of patients with available data on hemodynamic
variables. Additional sensitivity analyses included separate
analyses on patients with surgery performed in the same
hospital.
Treatment effect modification was investigated regarding
age groups, gender, period, and type of surgery (CABG,
aortic valve repair, or mitral valve repair).
All p values were two-tailed, and p < 0.05 was considered
statistically significant.
The number of cases in the registry during the study
period defined the sample size.
Analyses were all performed using the statistical
software R version 3.3.1. [24].
Results
Crude 30-day and 1-year mortality risks after admission
to the ICU for all 10,700 patients included in study were
1.9% (117/10,700) and 2.3% (250/10,700), respectively.
The final cohort for analysis of intraoperative inotrope
treatment consisted of 1452 patients.
Preoperation characteristics across treatment for these
patients are presented in Table 1, omitting 82 patients
receiving combination therapy. Being older, with lower
preoperative ejection fraction, higher EuroSCORE, and
longer time on cardiopulmonary bypass, and having
more complex surgery characterized patients receiving
milrinone.
Crude risks of 30-day and 1-year mortality for patients
receiving intraoperative dobutamine were 4.3% (18/418)
and 11.7% (49/418) respectively. Corresponding 30-day
and 1-year mortality risks for milrinone receivers were
8.5% (81/952) and 17.9% (170/952), and for patients
receiving combination therapy were 22% (18/82) and
37.8% (31/82).
Having excluded a theoretical beneficial effect of com-
bination therapy, figures and tables include only esti-
mates for milrinone versus dobutamine therapy.
Figure 2 shows these crude mortality risks as well as
standardized mortality risks by intraoperative treatment.
Table 2 presents the differences in standardized 30-day
and 1-year mortality according to intraoperative inotrope
treatment obtained from the main analysis and from
sensitivity analyses.
Treatment with milrinone was associated with standard-
ized 30-day mortality and 1-year mortality risk differences
of 4.1% (CI 1.2; 6.9, p < 0.01) and 4.8% (CI 0.4; 9.2, p =
0.03), respectively. Corresponding adjusted standardized
mortality for combination therapy was 13.2% (CI 5.4; 21.0,
p < 0.01) and 18.5% (CI 8.3; 28.8).
A total of 533 patients undergoing surgery at Aarhus
University Hospital had information on cardiac index
and central venous saturation prior to cardiopulmonary
bypass. Including these hemodynamic data in the regression
model, no significant difference between treatment groups
was evident (p = 0.60) (Table 2).
Although insignificant, sensitivity analyses analyzing
centers separately indicated a tendency toward increased
mortality associated with milrinone use in both centers
(Table 2).
According to the multiple logistic regression analysis,
older age, EuroSCORE, and surgery performed late in
the study period were also found to be independently associ-
ated with an increased 30-day mortality risk, whereas female
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gender, mitral valve surgery, and EuroSCORE were found
associated with increased 1-year mortality risk (Fig. 3).
Hemodynamic profiles in treatment groups were com-
parable in the immediate precardiopulmonary and post-
cardiopulmonary bypass periods, except for milrinone
receivers presenting with lower mean arterial blood
pressure. Hemodynamic variables are presented in
Additional file 2: Table S2.
Discussion
This retrospective study found intraoperative milrinone
treatment to be associated with an increased mortality
compared with dobutamine treatment in cardiac surgery
patients. The main analysis was supplemented with a
number of sensitivity analyses all confirming a tendency
toward increased mortality among milrinone receivers.
A few observational studies have reported increased
mortality associated with overall inotrope use in the cardiac
surgery setting [16, 25]. However, inconsistent data support
the superiority of one inotropic therapy over the other.
Accordingly, choice of inotropes in the treatment of cardiac
failure both in a post-bypass situation and in nonsurgical
heart failure seem to be largely guided by experts’ opinion
along with institutional and provider preference [26–29].
In Denmark, use of milrinone for cardiac failure following
cardiopulmonary bypass has increased at the expense of
dobutamine use. Milrinone was introduced as an agent
which, compared to dobutamine, cause reduced left and
right heart filling pressures due to its greater reduction in
vascular resistance, and thus superior to dobutamine in
treatment of low cardiac output syndrome following car-
diac surgery [30, 31]. However, in reviewing the literature,
we found only two randomized trials comparing the iso-
lated action of milrinone versus dobutamine in cardiac
surgery. The notion that milrinone is superior to dobuta-
mine seems to be based on one randomized trial including
120 patients randomized to either bolus and infusion
milrinone or infusion dobutamine (60 patients in each
treatment arm) if meeting an entry criterion of a cardiac
Table 1 Baseline characteristics
Variable Dobutamine
(n = 418)
Milrinone
(n = 952)
p value
Age group (years)
< 60 77 (18.4) 189 (19.9)
60–69 122 (29.2) 262 (27.5)
70–75 92 (22.0) 236 (24.8)
> 75 127 (30.4) 265 (27.8) 0.53
Gender
Female 138 (33.0) 253 (26.6) 0.02
LVEF
> 50% 189 (45.2) 347 (36.4)
30–50% 165 (39.5) 324 (34.0)
< 30% 64 (15.3) 281 (29.5) < 0.01
Modified EuroSCORE, mean (SD) 1.6 (1.5) 1.7 (1.5) 0.38
Time on CPB
Offpump 55 (13.2) 23 (2.4)
< 120 min 184 (44.0) 316 (33.2)
> 120 min 179 (42.8) 613 (64.4) < 0.01
Anesthesia
Intravenous 315 (75.4) 400 (42.0)
Volatile 103 (24.6) 552 (58) < 0.01
Year period
2006–2008 173 (41.4) 296 (31.1)
2009–2011 158 (37.8) 389 (40.9)
2012–2013 87 (20.8) 267 (28.0) < 0.01
Hospital
Aarhus UH 327 (78.2) 399 (41.9)
Aalborg UH 91 (21.8) 553 (58.1) < 0.01
Type of surgery
CABG only 143 (34.2) 277 (29.1) 0.07
Mitral valve 93 (22.2) 221 (23.2) 0.75
Aortic 125 (29.9) 352 (37.1) 0.01
Known milrinone preferencea (% of procedures)
< 48% 103 (45.0) 107 (19.9)
48–70% 65 (28.4) 113 (21.0)
70–83% 29 (12.7) 128 (23.8)
> 83% 32 (14.0) 189 (35.2) 0.01
Cardiac index (L/min/m2)
≤ 2 105 (50.5) 137 (50.6) 1.00
SvO2
≤ 60 30 (14.4) 51 (18.8) 0.25
Other intraoperative vasoactive support
Norepinephrine 196 (46.9) 719 (75.5) < 0.01
Epinephrine 13 (3.1) 114 (12.0) < 0.01
Dopamine 5 (1.2) 16 (1.7) 0.01
Levosimendan 7 (1.7) 1 (0.1) < 0.01
Table 1 Baseline characteristics (Continued)
Variable Dobutamine
(n = 418)
Milrinone
(n = 952)
p value
Postoperative mechanical support
ECMO 6 (1.4) 12 (1.3) 0.84
IABP 15 (3.6) 118 (12.4) < 0.01
Baseline characteristics according to intraoperative inotrope treatment.
Eighty-two patients in the mixture group were omitted. Data presented
as n (%) unless stated otherwise
LVEF left ventricular ejection fraction, SD standard deviation, CPB
cardiopulmonary bypass, UH University Hospital, CABG coronary artery
bypass grafting, SvO2 mixed venous oxygen saturation, ECMO
extracorporal membrane oxygenation, IABP intra-aortic balloon pump
aAttending anesthetist’s preference for milrinone was established as a
covariate stratified according to fraction of prior surgeries in which the
attending anesthetist used milrinone
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index < 2.0 L/min/m2 within 2 h after separation from
cardiopulmonary bypass [10]. Both drugs were found
equally effective to reverse low cardiac output after cardiac
surgery, and in subgroup analysis were equally effective at
treating pulmonary hypertension. More adverse events
were noted in the dobutamine arm with a higher incidence
of hypertension and atrial fibrillation, whereas milrinone
was associated with a higher incidence of bradycardia. The
study was not powered to estimate effect on mortality and
no long-term postoperative outcomes were reported.
The only other study, a small randomized study among
20 patients undergoing cardiac surgery, however, found
no marked differences in hemodynamic parameters
according to treatment with dobutamine or milrinone
[11]. The study provided no information on clinical
outcomes. Earlier trials comparing the efficacy of early-
generation phosphodiesterase inhibitors (maranon and
enoximone) with dobutamine similarly lack data on effect
on major clinical outcomes [4]. Recent meta-analyses of
randomized clinical trials with milrinone for cardiac
dysfunction conclude that the use of milrinone is neither
to be recommended nor refuted due to risk of bias and
random error in current evidence. None of the included
studies in these meta-analyses used dobutamine as a single
comparator [32, 33]. One study using network meta-
analytic data including indirect comparisons suggested no
big differences between milrinone and dobutamine in
cardiac surgery [34]. To date, the only randomized trial
sufficiently powered to establish the safety and efficacy
profile of milrinone was the OPTIME-CHF trial enrolling
951 patients with nonsurgical acute exacerbation of chronic
heart failure. The results of this trial suggested that
milrinone might be harmful in patients with ischemic
heart failure with LVEF < 40%. However, data are difficult
to interpret as the study allowed cointerventions with
dobutamine in randomized patients [35, 36].
Given the paucity of data from randomized trials, the
present observational study raises a highly relevant clinical
question regarding the perceived “superiority” of milrinone
compared to dobutamine as intraoperative treatment for
Fig. 2 Raw and standardized 30-day and 1-year mortality according
to inotrope treatment
Table 2 Difference in standardized mortality rates according to intraoperative inotrope treatment
Statistical model Number of patients Standardized risk difference (%)(95% CI) p value
Main analyses
Crude 30-day mortality, milrinone vs dobutamine 1452 4.2 (1.6; 6.8) < 0.01
Adjusted 30-day mortality, milrinone vs dobutamine 1452 4.1 (1.2; 6.9) < 0.01
Crude 1-year mortality, milrinone vs dobutamine 1452 6.1 (2.2; 10.1) < 0.01
Adjusted 1-year mortality, milrinone vs dobutamine 1452 4.8 (0.4; 9.2) 0.03
Sensitivity analyses on subpopulations
Adjustment for anesthetist’s preference of milrinone
Crude 30-day mortality, milrinone vs dobutamine 817 7.4 (4.4; 10.3) < 0.01
Adjusted 30-day mortality, milrinone vs dobutamine 817 6.2 (2.7; 9.6) < 0.01
Adjustment for hemodynamic status prior to cardiopulmonary bypass
Crude 30-day mortality, milrinone vs dobutamine 533 2.1 (−2.2; 6.4) 0.34
Adjusted 30-day mortality, milrinone vs dobutamine 533 1.4 (−3.6; 6.4) 0.59
Centers analyzed separately
Crude 30-day mortality Aarhus, milrinone vs dobutamine 726 3.4 (−0.1; 6.9) 0.06
Adjusted 30-day mortality Aarhus, milrinone vs dobutamine 726 3.7 (−0.2; 7.5) 0.06
Crude 30-day mortality Aalborg, milrinone vs dobutamine 644 6.5 (2.7; 10.3) < 0.01
Adjusted 30-day mortality Aalborg, milrinone vs dobutamine 644 6.2 (2.3; 10.2) < 0.01
CI confidence interval
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low cardiac output syndrome following cardiopulmonary
bypass. Particularly, in the light of results from the recent
levosimendan trials suggesting no major clinical improve-
ment using levosimendan in cardiac surgery [2, 9],
superiority of clinically relevant outcomes between “old”
inotropes remains an important clinical question.
The observed increased mortality associated with use
of milrinone might be associated with the potent vaso-
dilator effect of milrinone. Use of intravenous milrinone
is known to be associated with systemic hypotension,
and the safety margin could be significantly reduced if
volume loading is not optimized or patients are already
on vasopressor therapy [30, 37, 38]. Milrinone is often
given on a preemptive basis for patients with preoperative
low EF. However, the dosage and safety of preemptive
milrinone have never been uniformly established [39, 40].
Going off bypass is a period with huge changes in cardiac
filling pressures and milrinone loading could induce
severe hypotension, especially in patients already on
vasopressor therapy while on bypass. Vasoplegia following
cardiac surgery is a serious condition, implying a high risk of
postoperative organ failure and increased mortality [41, 42].
Clinicians may tend to perceive milrinone primarily as a
potent inotrope, whereas several studies indicate that milri-
none is mainly a potent vasodilator, with limited inotrope
properties against a fixed afterload [43, 44]. Thus, theoretical
advantages related to the afterload-reducing effects may be
diminished by the need for vasopressor therapy [4]. Recent
Fig. 3 Crude and adjusted odds ratios of 30-day and 1-year mortality according to inotrope regime. Simple model, unadjusted estimates; adjusted
model, estimates adjusted for listed covariates. Modified EuroSCORE is score on preoperative condition of chronic pulmonary disease, extracardiac
arteriopathy, neurological dysfunction, previous cardiac surgery, baseline plasma creatinine, active endocarditis, critical preoperative state, emer-
gency, recent myocardial infarction, pulmonary hypertension, and postinfarct septal rupture. OR odds ratio, CI confidence interval, EF preoperative
left ventricular ejection fraction, iv intravenous
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updates on inotropes for cardiac patients recommend that
dobutamine is preferable in clinical states characterized by
hypotension compared with milrinone [45].
Approximately one-third of patients in the present
study comprised patients with ischemic heart disease.
Accordingly, in reference to the results from the
OPTIME-CHF trial [36], this could additionally explain
the observed increased mortality associated with the
use of milrinone.
Use of milrinone has been considered particularly rele-
vant for patients with diastolic dysfunction or pulmonary
hypertension, but two trials challenge these notions.
Couture et al. [46] randomized 50 patients undergoing
CABG to receive milrinone or placebo starting before
CPB and continuing until skin closure. They found no
improvement in biventricular diastolic function. The
effects were only observed on systolic function. Denault
et al. [47] evaluated the efficacy of inhaled milrinone for
pulmonary hypertension and right ventricular dysfunction
on clinically relevant endpoints following high-risk cardiac
surgery patients in a recent study. Patients (N = 124) were
randomized to inhaled milrinone or placebo if presenting
with preoperative pulmonary hypertension (mean pulmon-
ary artery pressure > 30 mmHg or systolic pulmonary
pressure > 40 mmHg). Despite favorable hemodynamic
effects in the milrinone arm, milrinone did not facilitate
separation from cardiopulmonary bypass nor prevent
right ventricular failure. Accordingly, one could speculate
that clinicians may overvalue the effects of milrinone in
these special settings, and overlook the risk of the vasodila-
tion effects of milrinone in patients already presenting with
vasopressor dependency. Another comment should be
given on the dosage of dobutamine; commonly reported
dosages from older studies range from 10 to 20 μg/kg/min
[10]. Our current practice includes dobutamine doses in
the range of 5–8 μg/kg/min. Last but not least, milrinone is
eliminated via the kidneys and infusion should be adjusted
in patients with impaired kidney function. Unfortunately,
exact dosages of either inotropes were unavailable in our
study.
The low proportion of patients receiving inotropic
therapy (14%) indicates that inotropes were administered
not on a routine basis, but to the sickest patients. How-
ever, data did not allow determining whether inotropes
were used driven by a firm diagnosis of low cardiac output
syndrome. Data do not unveil the sequence of inotrope
treatment and hemodynamic status. Given this limitation,
however, hemodynamic variables might indicate that only
a smaller proportion of inotrope receivers suffered from
postcardiopulmonary low cardiac output syndrome (Add-
itional file 2: Table S2).
We cannot completely exclude that adjusted mortality is
influenced by differences in disease severity, but sensitivity
analyses including adjustment for precardiopulmonary
hemodynamic status aimed to ensure that treatment
groups were comparable before going on bypass. Further,
patients’ hemodynamic profiles were also comparable
between treatment groups in the immediate postcardiopul-
monary period, except for milrinone receivers presenting
with lower mean arterial blood pressure.
The present study illustrates that “new” drugs should
not be administered before large, pragmatic, high-quality
multicenter randomized controlled trials have been per-
formed. Proof of benefit and safety profiles between
dobutamine and milrinone have never been properly
characterized, as both catecholamines and phospho-
diesterase inhibitors were established before long-term
outcome testing became mandatory. Thus, the present
study adds important information to the existing literature
on the topic.
Our study has several strengths. It is the largest study
to date to compare mortality associated with the use of
the two most commonly used inotropes in Denmark.
Further, the strengths of this study include the population-
based nature of the cohort, with complete long-term
follow-up ensured by the unique personal identification
number. Included confounders were defined based on the
findings of a prior study identifying preoperative and intra-
operative factors associated with the use of inotrope therapy
[7]. Including these confounders into the g-formula,
adjustment was performed to control for indication bias.
The main limitation of the study is its observational nature.
The study shows associations, but cannot prove causality.
As with any statistical analysis, our ability to adjust for
potential confounding is limited to available data. By
performing analyses including the patient’s hemodynamic
profile prior to inotrope exposure and the anesthetists’
preferences of inotrope, attempts were made to adjust
for possible preference for one therapy over another,
and for patients with increased cardiac disease burden.
We recognize is a major limitation that 1/3 of cases
have missing data on their hemodynamic profile. How-
ever, hemodynamic data were considered missing at
random, as no systematic error could explain why data
had not been registered electronically. In terms of
understanding the indications for use of inotropes and
potential benefits or risks, the available hemodynamic
data were considered highly valuable and appropriate
for subgroup analysis. Preferably, the analyses should
also have included echocardiographic evaluations made
at the initiation of inotropic therapy. Unfortunately,
echocardiographic reports were not part of the standard
registration procedure in either hospital. Consequently,
echocardiographic data were not available. Hence, we
cannot rule out residual confounding of worse cardiac
performance among milrinone receivers, relating to
intraoperative factors such as reperfusion injury or
cardioplegia-induced myocardial dysfunction not necessarily
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accounted for by procedure scoring. Use of vasoconstrictors
was more common in the milrinone group, suggesting that
milrinone receivers were more hemodynamically unstable
than patients receiving dobutamine. Unfortunately, the data
did not allow establishing the sequence or dosage of other
vasoactive therapy. Accordingly, it is not possible to deter-
mine whether more frequent use of norepinephrine is to be
explained by hypotension caused by milrinone infusion, or if
milrinone was used as second-line inotrope therapy. Similar,
the more frequent use of postoperative mechanical support
among milrinone receivers suggests that these patients were
more hemodynamically unstable than their comparisons,
and that unmeasured confounding could bias results despite
adequate adjustment methods. None of the participating
centers followed a strict goal-directed therapy strategy
regarding the dosage of inotrope therapy, and it could be
discussed whether inotropes were administered in adequate
dosages and started and stopped appropriately. Neither did
data allow for subgroup analyses of a beneficial effect of
milrinone in patients on chronic beta-blocker treatment.
Conclusion
The retrospective data reported here indicate a possible
increased risk of mortality associated with the use of
intraoperative milrinone compared with use of dobutamine
among cardiac surgery patients. It is important to bear in
mind the possible bias due to the nature of the data.
However, the present results highlight the need for a
large-scale randomized trial to reevaluate possible harms
and benefits associated with the two most commonly used
inotropic agents used for low cardiac output syndrome in
cardiac surgery.
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